Aerovate Therapeutics (AVTE) Gets a Buy Rating from BTIG

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Aerovate Therapeutics (AVTEResearch Report), with a price target of $24.00. The company’s shares closed last Wednesday at $17.94.

According to, Harrison is ranked 0 out of 5 stars with an average return of -18.4% and a 31.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Prometheus Biosciences, and United Therapeutics.

Aerovate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $29.43 and a one-year low of $7.74. Currently, Aerovate Therapeutics has an average volume of 46.34K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.

Read More on AVTE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More